

Ref no: 194281218
From: Commercial
Date: 28/12/18
Subject: Compounded bevacizumab

REQUEST

- 1) Does your Trust have, or intend to introduce, a policy that makes compounded bevacizumab routinely available to treat wet age-related macular degeneration?

If yes please supply a copy of your policy.

Public interest arguments

There is a clear public interest for disclosure of this information, in that disclosure will:

- Further the understanding of and participation in the public debate of issues of the day, and will allow a more informed debate of issues under consideration by public bodies
- Promote accountability and transparency by public authorities for decisions taken by them
- Allow individuals to understand decisions made by public authorities affecting their lives and, in some cases, assisting individuals in challenging those decisions

RESPONSE

- 1) Does your Trust have, or intend to introduce, a policy that makes compounded bevacizumab routinely available to treat wet age-related macular degeneration?

Response:

The Trust is following the ongoing legal developments after publication of Justice Whipple's judicial review of the case between Bayer & Novartis and CCGs from the North East of England in September 2018. The outcome of the applications by Bayer and Novartis to the Court of Appeal is awaited. Presently, the Trust does not routinely procure or produce compounded bevacizumab for use in wet age-related macular degeneration. The Trust will review local policy following outcome of the legal proceedings. Any future review will be informed by liaison with other parties including other NHS hospitals trusts, commissioners, local, regional and national clinical, professional and regulatory groups.